These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16621589)

  • 41. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.
    Reyes-Soffer G; Rondon-Clavo C; Ginsberg HN
    Expert Opin Pharmacother; 2011 Jun; 12(9):1429-38. PubMed ID: 21426238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.
    Fazio S; Linton MF
    Curr Atheroscler Rep; 2004 Mar; 6(2):148-57. PubMed ID: 15023300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.
    Dayspring T; Pokrywka G
    Curr Atheroscler Rep; 2006 Sep; 8(5):356-64. PubMed ID: 16901405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment principles for the metabolic syndrome].
    Boulogne A; Vantyghem MC
    Presse Med; 2004 Jun; 33(10):673-81. PubMed ID: 15257242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Dyslipidemia and the metabolic syndrome].
    Soska V
    Vnitr Lek; 2003 Dec; 49(12):943-7. PubMed ID: 15040160
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A near future of treatment of dyslipidemia in type 2 diabetics].
    Vrablík M
    Vnitr Lek; 2016; 62(7-8):652-60. PubMed ID: 27627093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Nuclear receptors PPARalpha].
    Soska V
    Vnitr Lek; 2006 Jun; 52(6):628-31. PubMed ID: 16871768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting dyslipidemia in the metabolic syndrome: an update.
    Paraskevas KI; Karatzas G; Pantopoulou A; Iliopoulos DG; Perrea D
    Curr Vasc Pharmacol; 2010 Jul; 8(4):450-63. PubMed ID: 19485929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of fibric Acid derivatives in cardiovascular prevention.
    Khoury N; Goldberg AC
    Curr Treat Options Cardiovasc Med; 2011 Aug; 13(4):335-42. PubMed ID: 21544518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PPAR-α agonists are still on the rise: an update on clinical and experimental findings.
    Ferri N; Corsini A; Sirtori C; Ruscica M
    Expert Opin Investig Drugs; 2017 May; 26(5):593-602. PubMed ID: 28343425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential options to treat hypertriglyceridaemia.
    Viljoen A; Wierzbicki AS
    Curr Drug Targets; 2009 Apr; 10(4):356-62. PubMed ID: 19355860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strawberries, blueberries, and cranberries in the metabolic syndrome: clinical perspectives.
    Basu A; Lyons TJ
    J Agric Food Chem; 2012 Jun; 60(23):5687-92. PubMed ID: 22082311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of cardiovascular risk factors in patients with metabolic syndrome.
    de la Sierra A; Ruilope LM
    Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):209-14. PubMed ID: 17630947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.